Bellicum Pharma (BLCM) Misses Q2 EPS by 8c

Bellicum Pharma (NASDAQ: BLCM) reported Q2 EPS of ($0.74), $0.08 worse than the analyst estimate of ($0.66).

(emphasis Street Insider) “Since I joined the Company six months ago, we have conducted a thorough review of our strategy and operations, and are very optimistic about the opportunities before us,” said Rick Fair, Bellicum’s President & Chief Executive Officer. “We continue to be encouraged by the results from our ongoing BPX-501 pediatric studies and our progress toward a filing in Europe. We have adjusted our plans for U.S. registrational trials to enable an efficient path to seeking approvals for the greatest areas of unmet need. Lastly, we continue to be excited about the clinical progress of our CAR T and TCR product candidates, and the application of our molecular switch platform for future pipeline expansion.”

For earnings history and earnings-related data on Bellicum Pharma (BLCM) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• SeaStar Medical (ICU) Misses Q1 EPS by 4c
• Logistic Properties of the Americas (LPA) Reports Q2 results